INVO Bioscience, Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by INVO Bioscience, Inc. (the "Company") on February 23, 2023, reporting events occurring on February 17, 2023. The Company is a Nevada corporation with its principal executive offices in Sarasota, Florida. The filing details a private placement transaction involving debt and equity securities.
Key Financial Metrics and Transaction Details
- Debt Issuance: The Company issued a convertible debenture with an aggregate original principal amount of $200,000.
- Proceeds: The purchase price for the debenture was $180,000.
- Interest Rate: The debenture accrues interest at 8% per annum, payable on the maturity date of February 17, 2024.
- Equity Components:
- Warrant: Issued to purchase 100,000 shares of Common Stock at an exercise price of $0.75 per share.
- Commitment Shares: 33,333 shares of Common Stock issued as an inducement.
- Conversion Terms: The debenture is convertible into Common Stock at an initial fixed price of $0.52 per share, subject to anti-dilution adjustments and beneficial ownership limits.
- Transaction Costs: A cash fee of $14,400 was paid to Carter, Terry, & Company, Inc. as the placement agent.
- Use of Proceeds: Working capital and general corporate purposes.
Material Changes and Covenants
The filing does not provide comparative financial data (revenue, profit, or cash flow) for the period. The material change is the creation of a new direct financial obligation and the issuance of unregistered equity securities. Key covenants include:
- Beneficial Ownership Limit: Conversion is restricted if the holder would own more than 9.99% of outstanding Common Stock.
- Exchange Cap: Total shares issuable under this agreement and a related February 3, 2023 agreement are capped at 19.99% of outstanding shares (2,436,045 shares) unless shareholder approval is obtained.
- Prepayment: The Company may prepay the debenture at 105% of the principal amount plus accrued interest.
- Proceeds Sweep: If the Company raises more than $2,000,000 in aggregate cash proceeds, the buyer may require up to 50% of proceeds above that threshold to be used to repay the debenture. If proceeds are raised via an Equity Line of Credit before reaching the threshold, up to 25% may be required for repayment.
- Reserve Shares: The transfer agent has reserved 969,231 shares for conversion and warrant exercise.
Guidance, Risks, and Contingencies
The filing does not contain forward-looking guidance, management commentary on future performance, or specific risk factors beyond the contractual terms of the debenture. The primary contingency is the requirement for shareholder approval if the "Exchange Cap" is reached within 60 days, which constitutes an event of default if not procured.
Investor Verification Checklist
- Verify the current number of outstanding Common Stock shares to assess the dilution impact of the 2,436,045 share Exchange Cap.
- Confirm the Company's current cash position to evaluate the ability to service the $200,000 principal plus 8% interest due in February 2024.
- Review the related February 3, 2023 securities purchase agreement to understand the full scope of the 19.99% ownership cap.
- Monitor future capital raises to determine if the $2,000,000 "Minimum Threshold" is triggered, which could force immediate partial repayment of the debenture.
- Check for any subsequent filings regarding shareholder approval for the Exchange Cap.